Buy & Sell Royal Caribbean Cruises Ltd (RCL) – Royal Caribbean Cruises Ltd Price Today
Aura AI Summary
Key Stats
- $68.68BMarket Cap
- Consumer CyclicalSector
- -17.96%3M Drawdown
- $89.96BEnterprise Value
- 1.95%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 77 daysTypical Hold Time
Royal Caribbean Cruises Ltd (RCL) is currently valued at a market capitalization of $68.68B, with an enterprise value of $89.96B. Over the past 52 weeks, Royal Caribbean Cruises Ltd has traded between a low of $246.71 and a high of $365.84, highlighting its annual price range. Over the past three months, Royal Caribbean Cruises Ltd has recorded a drawdown of -17.96%, reflecting recent price volatility. Royal Caribbean Cruises Ltd offers a dividend yield of 1.95%, with the most recent dividend of $1.50 paid on 06 Mar 26. On average, investors hold Royal Caribbean Cruises Ltd for approximately 77 days, indicating typical investor behavior on the platform.
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Most Recent News
Emerson Electric partners with Aramco to develop advanced corrosion monitoring systems.
Emerson Electric announced a collaboration with Saudi Aramco to co-develop next-generation corrosion management solutions using ultrasonic online monitoring and wireless technology. This partnership aims to improve operational safety and performance ...

Modern inflation differs from the 1970s, driven by supply issues, not wage-price spirals.
Current inflation trends in the U.S. are often compared to the 1970s stagflation, but experts highlight key differences. Unlike the 1970s, today's inflation is driven mainly by supply-side pressures such as rising commodity prices and geopolitical te...

Atea Pharma shows low drug interaction risk for new Hepatitis C treatment and promising Hepatitis E antiviral data.
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
